Fennec banks positive results on heels of move to Nasdaq
October 19, 2017 at 08:40 AM EDT
Research Triangle Park-based Fennec Pharmaceuticals (Nasdaq: FENC) has banked positive Phase 3 results for its product for the prevention of hearing loss in pediatric cancer patients receiving chemotherapy.